REVIEW ARTICLE

Irinotecan Resistance Mechanisms in Cancer: Challenges and Opportunities

Bindu Ghodeswar[1,2*], Santosh Chhajed[2]

[1]*Amrutvahini College of Pharmacy, Sangamner, Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India.*
[2]*MET's Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik, Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India.*

Received: 18th May, 2024; Revised: 02nd May, 2024; Accepted: 08th June, 2024; Available Online: 25th June, 2024

ABSTRACT

Irinotecan, a topoisomerase I inhibitor, has been widely used in the treatment of various solid tumors, including colorectal, lung, and pancreatic cancers. However, its efficacy is often limited by the development of resistance mechanisms within cancer cells. Understanding these resistance mechanisms is crucial for improving treatment outcomes and developing effective therapeutic strategies. This review article provides a comprehensive overview of the mechanisms underlying irinotecan resistance in cancer. Key resistance mechanisms discussed include the overexpression of drug efflux pumps, activation of DNA repair pathways, altered drug metabolism, and microenvironmental factors. Clinical implications, challenges, and emerging opportunities in overcoming irinotecan resistance are also explored, including the identification of biomarkers predictive of response/resistance, combination therapies targeting multiple resistance pathways, and advancements in drug delivery systems. By elucidating the complexities of irinotecan resistance, this review aims to inform future research directions and facilitate the development of personalized treatment approaches for patients with resistant cancers.

Keywords: Irinotecan, Resistance mechanisms, Cancer treatment, Drug efflux pumps, DNA repair pathways, Drug metabolism, Tumor microenvironment, Biomarkers, Combination therapy, Drug delivery systems, Personalized medicine.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.74

How to cite this article: Ghodeswar B, Chhajed S. Irinotecan Resistance Mechanisms in Cancer: Challenges and Opportunities. International Journal of Drug Delivery Technology. 2024;14(2):1099-1105.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Cancer treatment has witnessed remarkable strides with the emergence of irinotecan, a formidable player in the fight against solid tumors, notably colorectal and lung cancers. Irinotecan's journey from discovery to clinical application epitomizes the relentless pursuit of more effective therapies against this formidable disease.[1]

Irinotecan, also known by its brand name Camptosar, belongs to the class of topoisomerase I inhibitors. It was first synthesized in the 1960s, but its therapeutic potential in cancer treatment was realized much later. Irinotecan gained approval from regulatory authorities, such as the U.S. Food and Drug Administration (FDA), in the late 1990s, marking a significant milestone in oncology.[2]

Solid tumors, including colorectal and lung cancers, pose significant challenges due to their aggressive nature and limited treatment options. Irinotecan, however, has emerged as a cornerstone in the management of these malignancies. Its efficacy extends to various stages of cancer, offering hope to patients facing daunting prognoses.[3]

Central to irinotecan's therapeutic prowess is its unique mechanism of action, which disrupts vital cellular processes within cancer cells. At the heart of the irinotecan mechanism lays its ability to inhibit DNA topoisomerase I, an enzyme pivotal for maintaining DNA integrity during replication and transcription. By binding to the enzyme-DNA complex, irinotecan prevents the resealing of DNA strands, leading to the accumulation of DNA breaks. The accumulation of DNA breaks inflicted by irinotecan sets in motion a cascade of events culminating in cell death. As cancer cells attempt to repair the DNA damage, they become vulnerable to additional insults, ultimately succumbing to apoptosis or programmed cell death. The inhibition of DNA topoisomerase I by irinotecan not only halts cancer cell proliferation but also impedes tumor progression. Its cytotoxic effects target actively dividing cancer cells, thereby curbing tumor growth and metastasis.[4]

Figures 1 and 2 illustrates the metabolic pathway of irinotecan, including its conversion to the active metabolite SN-38 and subsequent inhibition of topoisomerase I leading to DNA damage and cell death triggered by irinotecan, respectively.

**Author for Correspondence: pikbinbg@gmail.com*



Figure 1: Schematic diagram of irinotecan metabolism and mechanism of action

In essence, irinotecan's multifaceted mechanism underscores its efficacy in combating solid tumors, offering patients a ray of hope in their battle against cancer. As research continues to unravel its intricacies, irinotecan remains a cornerstone in the evolving landscape of cancer therapeutics.

Cancer treatment, despite significant advancements, often encounters a formidable adversary: Drug resistance. In the case of irinotecan, elucidating the mechanisms through which cancer cells evade its effects is paramount for improving patient outcomes and refining treatment strategies.

Cancer cells possess an innate ability to adapt and evolve, rendering them resistant to the cytotoxic effects of irinotecan. This resistance can manifest through various mechanisms, including enhanced drug efflux, alterations in drug targets, activation of survival pathways, and impaired apoptotic machinery. As cancer cells acquire these resistance mechanisms, they evade the lethal effects of irinotecan, leading to treatment failure and disease progression.

Understanding the intricacies of irinotecan resistance holds profound implications for patient care. By unraveling the molecular pathways involved, clinicians can tailor treatment regimens to target specific resistance mechanisms, thereby circumventing treatment resistance and improving patient outcomes.[5]

This review aims to provide a comprehensive examination of the diverse mechanisms underlying irinotecan resistance in cancer, shedding light on its clinical implications, challenges, and emerging opportunities. Through a systematic analysis of preclinical and clinical studies, this review will delve into the molecular mechanisms through which cancer cells evade the cytotoxic effects of irinotecan. From alterations in drug metabolism to activation of pro-survival signaling pathways, each resistance mechanism will be dissected to elucidate its role in treatment failure.

By synthesizing existing evidence, this review will delineate the clinical implications of irinotecan resistance, including its impact on treatment outcomes, patient prognosis, and therapeutic decision-making. Moreover, the review will highlight the challenges encountered in overcoming irinotecan resistance, ranging from tumor heterogeneity to off-target toxicities, and discuss strategies to address these challenges.



Figure 2: Cell death mechanisms triggered by irinotecan

Finally, the review will explore emerging opportunities in the field of irinotecan resistance research, including the identification of novel biomarkers, the development of targeted therapies, and the integration of immunotherapy approaches. By delineating future directions for research and clinical practice, this review aims to catalyze efforts towards overcoming irinotecan resistance and improving patient care.

Mechanisms of Irinotecan Resistance

Figure 3 depicts the various mechanisms underlying irinotecan resistance, such as drug efflux pumps, altered drug metabolism, and microenvironmental factors.

Drug efflux pumps

- *ATP-binding cassette transporters*

These transporters play a pivotal role in pumping out chemotherapeutic agents, including irinotecan, thereby reducing their intracellular concentration and efficacy. Among these transporters, P-glycoprotein (P-gp) stands out as a prominent player in irinotecan resistance.[6]

- *Efflux pump inhibitors*

Efforts to overcome P-gp-mediated resistance have led to the investigation of efflux pump inhibitors such as tariquidar and elacridar. These agents work by blocking the activity of P-gp, thereby restoring intracellular concentrations of irinotecan and enhancing its cytotoxic effects.[7]

Activation of DNA repair mechanisms

- *DNA repair pathways*

In response to irinotecan-induced DNA damage, cancer cells activate various DNA repair mechanisms as a survival



Figure 3: Mechanisms of irinotecan resistance in cancer cells

strategy, diminishing the efficacy of the drug. Key players in this process include poly(ADP-ribose) polymerase (PARP) and ATM kinase, which orchestrate DNA damage repair and promote cell survival.[8]

- *Therapeutic targets*

Targeting proteins involved in DNA repair pathways, such as PARP and ATM kinase, holds promise as a therapeutic strategy to overcome irinotecan resistance. By disrupting these repair mechanisms, it is possible to potentiate the cytotoxic effects of irinotecan and improve treatment outcomes.[9]

Altered drug metabolism

- *Variations in UGT1A1 activity*

Variations in the activity of UDP-glucuronosyltransferase 1A1 (UGT1A1), primarily due to genetic polymorphisms, can impact the metabolism of irinotecan into its active form, SN-38. Reduced UGT1A1 activity leads to decreased conversion of irinotecan, resulting in lower levels of the active drug within cancer cells.[10]

- *Clinical implications*

The impact of UGT1A1 polymorphisms extends to irinotecan toxicity and efficacy, particularly in patients with Gilbert's syndrome, who exhibit impaired UGT1A1 function. Understanding the role of UGT1A1 polymorphisms in irinotecan metabolism is essential for optimizing dosing regimens and minimizing treatment-related adverse effects.

Tumor microenvironment factors

- *Hypoxia*

Hypoxia within the tumor microenvironment can induce resistance to irinotecan through multiple mechanisms, including the upregulation of drug efflux pumps and activation of pro-survival signaling pathways. These adaptive responses enable cancer cells to survive and proliferate despite irinotecan treatment.

Physical barriers

Additionally, stromal cells and extracellular matrix components create physical barriers within the tumor microenvironment, hindering the penetration of irinotecan into tumor tissues. As a result, the efficacy of irinotecan is compromised.[11]

The illustration given in Figure 4 depicts how hypoxia, stromal interactions, and angiogenesis within the tumor microenvironment influence irinotecan efficacy and resistance through various mechanisms, such as upregulation of drug efflux pumps and promotion of pro-survival signaling pathways.

Table 1 provides a concise summary of the main mechanisms underlying irinotecan resistance in cancer, including brief descriptions of each mechanism, key proteins involved, and potential strategies to overcome resistance.

Clinical Implications and Challenges

Impact on treatment outcomes

- *Association with poor treatment outcomes*

Clinical evidence unequivocally establishes a correlation between irinotecan resistance and unfavorable treatment outcomes in cancer patients. Studies have consistently demonstrated lower response rates, decreased progression-free survival, and shorter overall survival in patients with irinotecan-resistant tumors compared to those with irinotecan-sensitive disease.[12]

- *Challenges in management*

Irinotecan resistance poses significant challenges in the management of various cancer types, including colorectal cancer, lung cancer, and pancreatic cancer. Despite its initial efficacy, the emergence of resistance limits the long-term benefits of irinotecan-based therapies, necessitating the exploration of alternative treatment strategies to improve patient outcomes.[13,14]

Table 2 summarizes selected clinical studies investigating irinotecan resistance in different cancer types, including details on study design, treatment regimens, response rates, progression-free survival, overall survival, and key findings.[15,16]

Identification of Biomarkers

Biomarkers associated with irinotecan response/resistance

Biomarkers associated with irinotecan response/resistance offer valuable insights into patient stratification and treatment selection. Key biomarkers include the UGT1A1 genotype, expression levels of drug efflux pumps (e.g., P-glycoprotein), and mutations in DNA repair genes (e.g., BRCA1/2). These biomarkers provide predictive and prognostic information, aiding in personalized treatment approaches.[17,18]

Table 3 provides a summary of biomarkers associated with irinotecan response or resistance, including their descriptions and clinical relevance in predicting treatment outcomes and guiding personalized medicine approaches.[19,20]

Limitations and challenges

Despite their potential utility, the discovery and validation of biomarkers for irinotecan response/resistance face several limitations and challenges. Tumor heterogeneity, inter-patient variability, and technical constraints hinder the accurate

Table 1: Summary of irinotecan resistance mechanisms

Irinotecan resistance mechanisms	*Description*	*Examples*	*Strategies*	*Clinical relevance*
Drug efflux pumps	Mechanism: The excessive production of ATP-binding cassette (ABC) transporters, specifically P-glycoprotein (P-gp), results in the enhanced removal of irinotecan from cancer cells..	ABCC1 (MRP1), ABCG2 (BCRP)	Efflux pump inhibitors (e.g., tariquidar, elacridar)	Associated with multidrug resistance phenotype; correlates with poor response to chemotherapy; potential target for combination therapy.
Activation of DNA repair mechanisms	Mechanism: Upregulation of DNA repair pathways in response to irinotecan-induced DNA damage, leading to enhanced repair and reduced cytotoxicity.	DNA polymerases, etc.	Targeting DNA repair pathways (e.g., PARP inhibitors, ATM inhibitors)	Contributes to acquired resistance to irinotecan-based therapy; associated with poorer prognosis; potential for combination with DNA repair inhibitors.
Altered drug metabolism	Mechanism: Variations in UDP-glucuronosyltransferase 1A1 (UGT1A1) activity due to genetic polymorphisms affecting the metabolism of irinotecan.	UGT1A1*28 polymorphism	Dose adjustment based on UGT1A1 genotype	Genetic determinant of irinotecan toxicity (e.g., neutropenia, diarrhea); influences pharmacokinetics and efficacy; considerations for personalized dosing.
Tumor microenvironment factors	Mechanism: Influence of hypoxia, stromal interactions, and angiogenesis on irinotecan efficacy and resistance within the tumor microenvironment.	Hypoxia, cancer-associated fibroblasts, angiogenic factors	Targeting hypoxia (e.g., hypoxia-activated prodrugs), stromal targeting agents, anti-angiogenic therapy	Impedes drug delivery to tumor cells; promotes survival and proliferation; associated with poor treatment response; rationale for combination with microenvironment-modulating agents.

Table 2: Clinical studies demonstrating irinotecan resistance in various cancer types

Cancer type	*Study design*	*Treatment regimen*	*Key findings*
Colorectal cancer	Prospective cohort	Irinotecan monotherapy	Identified high expression of drug efflux pumps as predictors of irinotecan resistance; poor prognosis in resistant patients.
Lung cancer	Retrospective cohort	Irinotecan plus cisplatin	Higher incidence of DNA repair gene mutations in non-responders; association with shorter survival outcomes.
Pancreatic cancer	Phase II clinical trial	Irinotecan plus gemcitabine	Demonstrated limited efficacy of irinotecan-based regimen; frequent development of resistance; need for alternative strategies.

Table 3: Biomarkers associated with irinotecan response/resistance

Biomarker	*Description*	*Clinical relevance*
UGT1A1 genotype	Polymorphisms in the UGT1A1 gene affecting enzyme activity and irinotecan metabolism.	- Homozygous 28 allele associated with reduced enzyme activity and increased risk of toxicity. - Homozygous 28/28 genotype linked to higher incidence of neutropenia and diarrhea.
Expression of drug efflux pumps	Overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp).	- High expression levels of P-gp correlated with reduced intracellular accumulation of irinotecan and poorer response to therapy.
DNA repair gene mutations	Mutations in BRCA1	- Mutations impairing DNA repair mechanisms associated with increased genomic instability and resistance to DNA-damaging agents like irinotecan.

assessment of biomarker status, complicating their translation into clinical practice. Moreover, the dynamic nature of tumor biology necessitates ongoing validation and refinement of biomarker assays.

Combination Strategies to Overcome Resistance

Use of combination therapies

Preclinical and clinical studies support the rationale for employing combination therapies to overcome irinotecan resistance. Co-administration of irinotecan with other chemotherapy agents or targeted therapies has shown promise in circumventing resistance mechanisms and enhancing treatment efficacy. These combination strategies leverage complementary mechanisms of action to synergistically target cancer cells and overcome resistance pathways.[21]

Exploration of synergistic effects

Combining irinotecan with other drugs, such as fluoropyrimidines, oxaliplatin, and anti-angiogenic agents, holds the potential for achieving synergistic effects and overcoming resistance. By exploiting distinct pathways



Figure 4: Tumor microenvironment factors contributing to irinotecan resistance

involved in tumor growth and survival, combination therapies offer a comprehensive approach to combatting irinotecan resistance and improving patient outcomes. Efforts to address irinotecan resistance encompass a multifaceted approach, spanning from biomarker identification to the development of innovative combination strategies. Overcoming the clinical implications and challenges associated with irinotecan resistance is imperative for optimizing treatment outcomes and advancing the field of cancer therapeutics.[22]

Figure 5 illustrates various therapeutic strategies to overcome irinotecan resistance, including combination therapies targeting multiple resistance mechanisms, drug delivery systems enhancing drug delivery to tumor tissues, and personalized medicine approaches based on biomarker profiling.

Emerging Opportunities and Future Directions

Advancements in drug delivery

- *Nanotechnology-based approaches*

Nanotechnology offers promising avenues for enhancing the delivery of irinotecan to tumor tissues. Nanoparticle formulations and liposomal carriers provide precise control over drug release kinetics and improve drug pharmacokinetics, thereby enhancing the therapeutic efficacy of irinotecan while minimizing systemic toxicity.[23]

- *Targeted drug delivery systems*

It selectively delivers irinotecan to cancer cells while sparing healthy tissues. By leveraging tumor-specific biomarkers or exploiting the unique properties of the tumor microenvironment, these systems enhance drug accumulation within tumors and reduce off-target effects, thereby improving treatment outcomes.[24]



Figure 5: Strategies to overcome irinotecan resistance

Precision Medicine Approaches

Genomic and transcriptomic profiling

Genomic and transcriptomic profiling holds immense potential for identifying predictive biomarkers of irinotecan response/resistance.[25]

Integration of omics data

Ongoing initiatives, such as basket trials and umbrella trials, seek to integrate omics data into clinical practice to guide treatment decision-making. By stratifying patients based on molecular subtypes and identifying actionable targets, these trials pave the way for precision medicine approaches in irinotecan-based therapies.[26,27]

Immunotherapy and Irinotecan

Immunomodulatory effects of irinotecan

Irinotecan exhibits immunomodulatory effects that hold promise for enhancing antitumor immune responses. By promoting tumor immunogenicity and modulating the tumor microenvironment, irinotecan can augment the efficacy of immunotherapy approaches and potentiate antitumor immune responses.[28,29]

Clinical trials investigating combination therapies

Ongoing clinical trials are investigating the combination of irinotecan with immune checkpoint inhibitors, cytokines, and adoptive cell therapies. These combination approaches aim to harness the synergistic effects of irinotecan-induced cytotoxicity and immunomodulation, offering new avenues for improving treatment outcomes in cancer patients.[30,31]

CONCLUSION

In this review, we have delved into the multifaceted landscape of irinotecan resistance in cancer treatment. We explored the intricate mechanisms underlying resistance, including drug efflux pumps, activation of DNA repair mechanisms, altered drug metabolism, and tumor microenvironment factors. Additionally, we discussed the clinical implications of irinotecan resistance, its impact on treatment outcomes across various cancer types, and the challenges it poses in clinical management. Furthermore, we highlighted emerging opportunities such as advancements in drug delivery, precision medicine approaches, and the integration of immunotherapy with irinotecan.

The findings underscore the critical importance of overcoming irinotecan resistance in improving cancer treatment outcomes and enhancing patient care. As resistance mechanisms continue to evolve and present challenges in clinical management, future research endeavors must focus on unraveling the complexities of resistance and developing innovative therapeutic strategies. Moreover, in clinical practice, a personalized approach that incorporates biomarker-guided treatment selection and combination therapies holds promise for overcoming irinotecan resistance and improving patient outcomes.

In conclusion, overcoming irinotecan resistance stands as a pivotal challenge in the field of oncology, with profound implications for cancer outcomes and patient survival. As we navigate the complexities of resistance mechanisms and explore novel therapeutic avenues, it is essential to recognize the enduring significance of this endeavor in the quest to conquer cancer. Through concerted research efforts and collaborative initiatives, we can advance our understanding of irinotecan resistance and pave the way for transformative advancements in cancer therapy. Ultimately, the pursuit of overcoming irinotecan resistance represents a beacon of hope for patients and a testament to the relentless pursuit of excellence in oncology.

REFERENCES

1. Toledo B, Deiana C, Scianò F, Brandi G, Marchal JA, Perán M, Giovannetti E. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives. Expert Review of Clinical Pharmacology. 2024 Apr 2(just-accepted).https://doi.org/10.1080/17512433.2024.2319340
2. Khaiwa N, Maarouf NR, Darwish MH, Alhamad DW, Sebastian A, Hamad M, Omar HA, Orive G, Al-Tel TH. Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise. European journal of medicinal chemistry. 2021 Nov 5;223:113639.https://doi.org/10.1016/j.ejmech.2021.113639
3. Pal M, Muinao T, Boruah HP, Mahindroo N. Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges. Biomedicine & Pharmacotherapy. 2022 Feb 1;146:112488.https://doi.org/10.1016/j.biopha.2021.112488
4. Wang T, Li X, Ma R, Sun J, Huang S, Sun Z, Wang M. Advancements in colorectal cancer research: Unveiling the cellular and molecular mechanisms of neddylation. International Journal of Oncology. 2024 Apr 1;64(4):1-4.https://doi.org/10.3892/ijo.2024.5627
5. Huang CY, Pai YC, Yu LC. Glucose conferred irinotecan chemoresistance through divergent actions of pyruvate and ATP in cell death and proliferation of colorectal cancer. Oncology. 2022 Oct 3;100(10):555-68.https://doi.org/10.1159/000525977
6. Ozawa S, Miura T, Terashima J, Habano W. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resistance. 2021;4(4):946. 10.20517/cdr.2021.82
7. Wu ZX, Yang Y, Zeng L, Patel H, Bo L, Lin L, Chen ZS. Establishment and characterization of an irinotecan-resistant human colon cancer cell line. Frontiers in oncology. 2021 Feb 22;10:624954.https://doi.org/10.3389/fonc.2020.624954
8. Kumar S, Sherman MY. Resistance to TOP-1 inhibitors: good old drugs still can surprise us. International Journal of Molecular Sciences. 2023 Apr 13;24(8):7233.https://doi.org/10.3390/ijms24087233
9. Kurter H, Yeşil J, Daskin E, KOÇAL GÇ, Ellidokuz HÜ, BAŞBINAR Y. Drug resistance mechanisms on colorectal cancer. Journal of Basic and Clinical Health Sciences. 2021 Jan 1;5(1):88-93.https://doi.org/10.30621/jbachs.869310
10. Su YY, Chiang NJ, Chang JS, Wang YW, Shen BN, Li YJ, Hwang DY, Shan YS, Chen LT. The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. ESMO open. 2023 Feb 1;8(1):100746.https://doi.org/10.1016/j.esmoop.2022.100746
11. Yue B, Gao R, Wang Z, Dou W. Microbiota-host-irinotecan axis: a new insight toward irinotecan chemotherapy. Frontiers in Cellular and Infection Microbiology. 2021 Oct 14;11:710945. https://doi.org/10.3389/fcimb.2021.710945
12. Luo M, Yang X, Chen HN, Nice EC, Huang C. Drug resistance in colorectal cancer: An epigenetic overview.

BiochimicaetBiophysicaActa (BBA)-Reviews on Cancer. 2021 Dec 1;1876(2):188623.https://doi.org/10.1016/j.bbcan.2021.188623

13. Chakrabarti S, Kamgar M, Mahipal A. Systemic therapy of metastatic pancreatic adenocarcinoma: Current status, challenges, and opportunities. Cancers. 2022 May 24;14(11):2588. https://doi.org/10.3390/cancers14112588
14. Bragagnoli AC, Araujo RL, Ferraz MW, Dos Santos LV, Abdalla KC, Comar F, Santos FA, Oliveira MA, Carvalheira JB, Cárcano FM, da SilveiraNogueira Lima JP. Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial. British Journal of Cancer. 2021 Mar 16;124(6):1072-8.https://doi.org/10.1038/s41416-020-01208-6
15. Badin F. Considerations for Selecting Second-Line Treatment in Patients With Progressive Small Cell Lung Cancer and the Use of Lurbinectedin in This Setting. Cancer Treatment and Research Communications. 2024 Feb 29:100803.https://doi.org/10.1016/j.ctarc.2024.100803
16. Kasi A, McGinnis T, Naik G, Handa S, Williams G, Paluri R. Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. Journal of Gastrointestinal Oncology. 2021 Apr;12(2):464.10.21037/jgo-20-338
17. Pliakou E, Lampropoulou DI, Dovrolis N, Chrysikos D, Filippou D, Papadimitriou C, Vezakis A, Aravantinos G, Gazouli M. Circulating miRNA expression profiles and machine learning models in association with response to irinotecan-based treatment in metastatic colorectal cancer. International Journal of Molecular Sciences. 2022 Dec 20;24(1):46.https://doi.org/10.3390/ijms24010046
18. Kamgar M, Mehdi M, Thapa B, Szabo A, Ahmed G, Shreenivas A, Thomas JP, Sriram D, Evans DB, Tsai S, Christians KK. AtmOr Chek2 Alterations as Potential Biomarkers of Improved Outcomes with Irinotecan: Real-World Analysis of Advanced Pancreatic Ductal Adenocarcinoma.http://dx.doi.org/10.2139/ssrn.4647297
19. Varshney P, Sharma V, Yadav D, Kumar Y, Singh A, Kagithala NR, Sharma PK, Porwal O, Fuloria NK, Sharma PK, Gupta AK. The Impacts and Changes Related to the Cancer Drug Resistance Mechanism. Current drug metabolism. 2023 Dec 1;24(12):787-802.https://doi.org/10.2174/0113892002266408231207150547
20. Marks EI, Matera R, Olszewski AJ, Yakirevich E, El-Deiry WS, Safran H, Carneiro BA. Mutations in DNA repair genes and clinical outcomes of patients with metastatic colorectal cancer receiving Oxaliplatin or Irinotecan-containing Regimens. American Journal of Clinical Oncology. 2021 Feb 1;44(2):68-73.10.1097/COC.0000000000000785
21. Chai Y, Liu JL, Zhang S, Li N, Xu DQ, Liu WJ, Fu RJ, Tang YP. The effective combination therapies with irinotecan for colorectal cancer. Frontiers in Pharmacology. 2024 Feb 5;15:1356708.https://doi.org/10.3389/fphar.2024.1356708
22. Duarte D, Vale N. Combining repurposed drugs to treat colorectal cancer. Drug Discovery Today. 2022 Jan 1;27(1):165-84.https://doi.org/10.1016/j.drudis.2021.09.012
23. Fathi-Karkan S, Qindeel M, Arshad R, Moafian Z, Ghazy E, Rahdar A, Ghotekar S. Recent advancements in Irinotecan-loaded nanomaterials as a smart drug delivery system for cancer therapy: A state-of-art-review. Inorganic Chemistry Communications. 2024 Jan 9:112028.https://doi.org/10.1016/j.inoche.2024.112028
24. Khan MI, Hossain MI, Hossain MK, Rubel MH, Hossain KM, Mahfuz AM, Anik MI. Recent progress in nanostructured smart drug delivery systems for cancer therapy: a review. ACS Applied Bio Materials. 2022 Feb 28;5(3):971-1012.https://doi.org/10.1021/acsabm.2c00002
25. Ponomaryova AA, Rykova EY, Solovyova AI, Tarasova AS, Kostromitsky DN, Dobrodeev AY, Afanasiev SA, Cherdyntseva NV. Genomic and transcriptomic research in the discovery and application of colorectal cancer circulating markers. International Journal of Molecular Sciences. 2023 Aug 3;24(15):12407.https://doi.org/10.3390/ijms241512407
26. Krentel F, Singer F, Rosano-Gonzalez ML, Gibb EA, Liu Y, Davicioni E, Keller N, Stekhoven DJ, Kruithof-de Julio M, Seiler R. A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. Scientific Reports. 2021 Mar 12;11(1):5849. https://doi.org/10.1038/s41598-021-85151-3
27. Ng M, Chen S, Ong WS, Balachander A, Seet A, Yeong J, Sutiman N, Lim TK, Lee B, Guo YA, Leong WF. A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects. International Journal of Cancer. 2022 Aug 1;151(3):435-49.https://doi.org/10.1002/ijc.34021
28. Zhou C, Cheng X, Tu S. Current status and future perspective of immune checkpoint inhibitors in colorectal cancer. Cancer letters. 2021 Nov 28;521:119-29. https://doi.org/10.1016/j.canlet.2021.07.023
29. Tare H, Vaidya V, Fulmali S, Jadhao S, Wankhade M, Bhise M. Transcriptomic Insight and Structural Integration: Repositioning FDA-Approved Methotrexate Derivative for Precision Therapy in Lung Cancer through Drug-Drug Similarity Analysis and Cavity-Guided Blind Docking. International Research Journal of Multidisciplinary Scope (IRJMS), 2024; 5(1): 631-639. DOI: 10.47857/irjms.2024.v05i01.0300
30. Alkhatib MH, Zahim DK, Backer WS. Anticancer activity of mixed doxorubicin and pravastatin in nanoemulsions against HCT 116 colon cancer cells. International Journal of Drug Delivery Technology. 2017 Jan 1;7(1):63-70.
31. Al-Ani AA, Hussein AN, Ali ZA. In Silico Design, Synthesis, and Characterization of Ibuprofen Derivative as Potential Antitumor Agent. International Journal of Pharmaceutical Quality Assurance. 2019;10:77-80.